Bruce Turner - 02 Oct 2023 Form 3 Insider Report for Immunome Inc. (IMNM)

Role: Chief Strategy Officer
Signature: /s/ Sandra Stoneman, Attorney-in-Fact
Issuer symbol: IMNM
Transactions as of: 02 Oct 2023
Net transactions value: $0
Form type: 3
Filing time: 04 Oct 2023, 17:29:55 UTC
Next filing: 13 Aug 2024
SEC: View on sec.gov

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Underlying Class	Amount	Exercise Price	Ownership	Footnotes
holding	IMNM	Stock Option (Right to Buy)							02 Oct 2023	Common Stock	349,740	$1.06	Direct	F1, F2

* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id	Content
F1	25% of the shares will vest on March 1, 2024, and the remaining shares shall vest in 36 equal monthly installments thereafter.
F2	Dr. Turner was appointed as Chief Strategy Officer of the Issuer effective immediately after the Effective Time (as defined in the Agreement and Plan of Merger and Reorganization dated June 29, 2023 (the "Merger Agreement"), by and among the Issuer, Ibiza Merger Sub, Inc., and Morphimmune Inc.). In connection with the Closing (as defined in the Merger Agreement) and prior to Dr. Turner being appointed an executive officer of the Issuer, Dr. Turner exchanged his options to acquire shares of common stock of Morphimmune for options to acquire shares of the Issuer.

Content

25% of the shares will vest on March 1, 2024, and the remaining shares shall vest in 36 equal monthly installments thereafter.

Dr. Turner was appointed as Chief Strategy Officer of the Issuer effective immediately after the Effective Time (as defined in the Agreement and Plan of Merger and Reorganization dated June 29, 2023 (the "Merger Agreement"), by and among the Issuer, Ibiza Merger Sub, Inc., and Morphimmune Inc.). In connection with the Closing (as defined in the Merger Agreement) and prior to Dr. Turner being appointed an executive officer of the Issuer, Dr. Turner exchanged his options to acquire shares of common stock of Morphimmune for options to acquire shares of the Issuer.

Remarks:

See Attached Exhibit 24